Felix Aigner1, Johann Pratschke1, Moritz Schmelzle1. 1. Department of Surgery, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Campus Virchow-Klinikum, Berlin, Germany.
Abstract
BACKGROUND: Oligometastatic disease in colorectal cancer may affect the liver, lung, and peritoneum. This review mainly focuses on colorectal liver metastases (CRLM) and highlights recommendations and therapeutic strategies drawn from the current literature and consensus conferences. The following data address a paradigm shift in surgical approaches to CRLM, pushing the limits of multimodal treatment concepts. METHODS: A systematic review of the relevant literature on multimodal treatment strategies for synchronous and metachronous CRLM is presented. RESULTS: The choice of treatment strategy depends on the clinical scenario; however, perioperative chemotherapy and the liver-first concept in synchronous CRLM are favored with subsequent partial extended liver resection with or without various augmentation techniques for liver surgery. CONCLUSION: Surgical strategies should be strongly defined with regard to an adequate liver remnant. All patients with synchronous CRLM should be evaluated by a multidisciplinary team.
BACKGROUND:Oligometastatic disease in colorectal cancer may affect the liver, lung, and peritoneum. This review mainly focuses on colorectal liver metastases (CRLM) and highlights recommendations and therapeutic strategies drawn from the current literature and consensus conferences. The following data address a paradigm shift in surgical approaches to CRLM, pushing the limits of multimodal treatment concepts. METHODS: A systematic review of the relevant literature on multimodal treatment strategies for synchronous and metachronous CRLM is presented. RESULTS: The choice of treatment strategy depends on the clinical scenario; however, perioperative chemotherapy and the liver-first concept in synchronous CRLM are favored with subsequent partial extended liver resection with or without various augmentation techniques for liver surgery. CONCLUSION: Surgical strategies should be strongly defined with regard to an adequate liver remnant. All patients with synchronous CRLM should be evaluated by a multidisciplinary team.
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Oncol Date: 2013-10-11 Impact factor: 41.316
Authors: Mark G van Vledder; Mechteld C de Jong; Timothy M Pawlik; Richard D Schulick; Luis A Diaz; Michael A Choti Journal: J Gastrointest Surg Date: 2010-09-14 Impact factor: 3.452
Authors: S Jonas; A Thelen; C Benckert; A Spinelli; S Sammain; U Neumann; B Rudolph; P Neuhaus Journal: World J Surg Date: 2007-03 Impact factor: 3.352
Authors: Sebastian Stintzing; Dominik P Modest; Lisa Rossius; Markus M Lerch; Ludwig Fischer von Weikersthal; Thomas Decker; Alexander Kiani; Ursula Vehling-Kaiser; Salah-Eddin Al-Batran; Tobias Heintges; Christian Lerchenmüller; Christoph Kahl; Gernot Seipelt; Frank Kullmann; Martina Stauch; Werner Scheithauer; Swantje Held; Clemens Giessen-Jung; Markus Moehler; Andreas Jagenburg; Thomas Kirchner; Andreas Jung; Volker Heinemann Journal: Lancet Oncol Date: 2016-08-27 Impact factor: 41.316
Authors: Gunnar Folprecht; Thomas Gruenberger; Wolf O Bechstein; Hans-Rudolf Raab; Florian Lordick; Jörg T Hartmann; Hauke Lang; Andrea Frilling; Jan Stoehlmacher; Jürgen Weitz; Ralf Konopke; Christian Stroszczynski; Torsten Liersch; Detlev Ockert; Thomas Herrmann; Eray Goekkurt; Fabio Parisi; Claus-Henning Köhne Journal: Lancet Oncol Date: 2009-11-26 Impact factor: 41.316
Authors: René Adam; Aimery de Gramont; Joan Figueras; Norihiro Kokudo; Francis Kunstlinger; Evelyne Loyer; Graeme Poston; Philippe Rougier; Laura Rubbia-Brandt; Alberto Sobrero; Catherine Teh; Sabine Tejpar; Eric Van Cutsem; Jean-Nicolas Vauthey; Lars Påhlman Journal: Cancer Treat Rev Date: 2015-06-30 Impact factor: 12.111
Authors: S Acciuffi; F Meyer; A Bauschke; R Croner; U Settmacher; A Altendorf-Hofmann Journal: J Cancer Res Clin Oncol Date: 2021-12-16 Impact factor: 4.553